Los Angeles, CA
Primary service areas: CA, AZ, NV
Volume: 70,184 outpatient visits; 7,973 inpatient days; 60 beds
The USC Norris Comprehensive Cancer Center, located in Los Angeles, is a major regional and national resource for cancer research, treatment, prevention, and education.
Nearly 200 basic and population scientists, physicians from the faculty of the Keck School of Medicine of USC, and several USC professional schools/departments and the College of Letters, Arts and Sciences that are members of the USC Norris Comprehensive Cancer Center investigate the complex origins and progression of cancer, develop prevention strategies, and search for cures.
The National Cancer Institute (NCI) has designated the USC Norris Comprehensive Cancer Center as one of the nation's 40 comprehensive cancer centers, a select group of institutions providing leadership in cancer treatment, research, prevention, and education. USC Norris Comprehensive Cancer Center has held this designation since 1973, when it was named as one of the first 8 comprehensive cancer centers.
USC Norris Comprehensive Cancer Center scientists work toward a complete understanding of the most fundamental aspects of cancer. They study the abnormal cell growth characteristic of cancer to determine what goes wrong and how the process can be altered. They then work to quickly translate those findings into treatment and prevention strategies.
Over the years of its history, the Center has made many important scientific advances, including the development of a major classification scheme for lymphoma (Lukes), the discovery of the jun oncogone (Vogt), the elucidation of links between steroid hormones and breast and prostate cancer (Henderson, Ross, Pike, Bernstein, et al), the development of surgical techniques for orthotopic bladder reconstruction (Skinner), the establishment of the relationships between DNA methylation and cancer (Jones and Laird), the roles of glucose-regulated proteins in cancer (Lee), the development of molecular markers for neuroblastoma (Seeger), bladder cancer (Cote), and gastrointestinal cancers (Lenz), 8q24’s link to prostate and colon cancer (Haiman, Henderson), and the identification of a key genetic mutation in lymphoma development (Lieber).
Research at USC Norris Comprehensive Cancer Center is organized into 5 thematic programs (molecular genetics, epigenetics and regulation, tumor microenvironment, cancer epidemiology, and cancer control research), and 5 translational research programs (genitourinary cancers, gastrointestinal cancers, women’s cancers, leukemia and lymphoma, and a "bridge" program in developmental therapeutics, which acts as a conduit between the thematic and other translational programs). The formal program alignment of the USC Norris Comprehensive Cancer Center members has been carefully determined to promote the Center’s overall goal of fostering collaborative research in the areas of basic, clinical, epidemiological, cancer control, and translational research.
USC Norris Comprehensive Cancer Center members currently hold research grants totaling $134 million in direct costs, with $53 million of that coming from the NCI.
USC Norris Comprehensive Cancer Center provides comprehensive care for patients in its affiliated hospitals and outpatient clinics and conducts hundreds of clinical trials, offering the latest in innovative cancer treatments. USC Norris Comprehensive Cancer Center affiliated hospitals include the USC Norris Cancer Hospital, Children’s Hospital Los Angeles, USC University Hospital, and Los Angeles County + USC Medical Center, one of the largest teaching hospitals in the nation.
At each location, USC Norris Comprehensive Cancer Center physicians and scientists are dedicated to fighting the battle against cancer with patients, their families, and friends.